Immunodeficiency 19 (IMD19) Cell Models for Research

Immunodeficiency 19 (IMD19) is a rare primary immunodeficiency disorder caused by mutations in the NFKB1 gene. The exact prevalence is unknown, but it is estimated to affect a small number of individuals worldwide. The condition is characterized by recurrent infections, autoimmunity, and inflammatory complications. According to the National Institutes of Health (NIH), NFKB1 haploinsufficiency is the most common cause of common variable immunodeficiency (CVID)-like phenotype, accounting for approximately 4% of CVID cases. The clinical spectrum is broad, ranging from asymptomatic carriers to severe infections and lymphoproliferative disorders. Early diagnosis and management are critical to reduce morbidity and mortality.

IMD19 serves as an excellent model for studying NF-κB signaling, which is central to immune regulation, inflammation, and cancer. The disease provides a unique opportunity to investigate the molecular mechanisms of haploinsufficiency and dominant-negative effects. Public datasets, such as those from the European Society for Immunodeficiencies (ESID) registry, offer clinical and genetic data. However, many open questions remain regarding genotype-phenotype correlations and the development of targeted therapies. Gene-edited cell models, such as NFKB1 knockout and knock-in lines, are essential tools to dissect these mechanisms and screen for potential therapeutics.

IMD19 is primarily caused by mutations in NFKB1, which encodes the p50 subunit of the NF-κB transcription factor complex. The NF-κB pathway is a critical regulator of immune responses, cell survival, and proliferation. Pathogenic mechanisms include:

• • Haploinsufficiency: Loss-of-function mutations leading to reduced p50 protein levels, impairing canonical NF-κB signaling.
• • Dominant-negative effects: Some mutations result in a truncated protein that interferes with the function of the wild-type allele.
• • Impaired nuclear translocation: Mutations may affect the nuclear localization signal, preventing NF-κB from entering the nucleus to activate target genes.
• • Altered target gene expression: Dysregulation of NF-κB target genes, including cytokines, chemokines, and anti-apoptotic factors, contributes to immune deficiency and inflammation.

Data from TCGA, COSMIC, and ClinVar.

The NF-κB pathway is the central hub in IMD19. Key nodes include:

• • Canonical NF-κB signaling: Activation by TNF-α, IL-1, and TLR ligands leads to IKK-mediated phosphorylation and degradation of IκBα, allowing p50/p65 translocation.
• • Non-canonical NF-κB signaling: Involves processing of p100 to p52, regulated by NF-κB-inducing kinase (NIK) and IKKα.
• • Downstream effectors: Pro-inflammatory cytokines (IL-6, TNF-α), chemokines (IL-8), adhesion molecules (ICAM-1), and anti-apoptotic proteins (Bcl-2, c-IAP).
• • Cross-talk with other pathways: PI3K/AKT, MAPK, and JAK/STAT pathways interact with NF-κB to modulate immune responses.

Organoids derived from patient-derived induced pluripotent stem cells (iPSCs) offer a more physiologically relevant model, recapitulating immune cell development and function.

• • Genetically engineered mouse models (GEMMs): Nfkb1 knockout mice exhibit immune defects and increased susceptibility to infections, mimicking IMD19.
• • Patient-derived xenografts (PDX): Not commonly used for immune disorders but can be generated from patient PBMCs.
• • Induced models: CRISPR-mediated knockout of Nfkb1 in mouse zygotes or cell lines to study specific mutations.
• • Humanized mice: Engraftment of human immune cells into immunodeficient mice to study human NFKB1 mutations in vivo.

CRISPR-Cas9 gene editing enables the creation of isogenic cell lines with precise NFKB1 mutations. These models are invaluable for studying the functional consequences of specific variants. Examples include:

• • NFKB1 knockout cell lines: Complete loss of p50 expression to model haploinsufficiency.
• • NFKB1 point-mutation knock-in lines: Introduction of disease-associated missense mutations to study dominant-negative effects.
• • Reporter lines: NF-κB-responsive reporter genes (e.g., luciferase or GFP) to monitor pathway activity in real time.

These sequence-verified, commercially available models accelerate research by providing consistent and reproducible systems for drug screening and mechanistic studies.

Gene-edited cell lines are used to validate the functional impact of NFKB1 variants. For example, NFKB1 knockout cells show impaired cytokine production upon stimulation, confirming the role of p50 in immune responses. Knock-in lines with specific mutations can be compared to wild-type to assess dominant-negative effects. These models are also used in CRISPR screens to identify genetic modifiers of NF-κB signaling.

Isogenic pairs (wild-type vs. NFKB1 knockout) are used in high-throughput screening to identify compounds that selectively target NF-κB-deficient cells. This approach can reveal synthetic lethal interactions and potential therapeutic targets. Additionally, gene-edited lines can be used to study resistance mechanisms to NF-κB inhibitors, which are being explored as anti-inflammatory and anti-cancer agents.

CRISPR-based synthetic lethality screens using NFKB1 knockout lines can identify genes that are essential for cell survival in the absence of p50. These genes may serve as biomarkers for patient stratification or as novel drug targets. Furthermore, gene-edited models can be used to identify secreted proteins that reflect the immune dysregulation in IMD19, aiding in the development of diagnostic biomarkers.